Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Costanza Bertoni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: HIV Infections, Hepatitis B, Chronic, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors..
Abstract (Originalsprache)
We investigated factors associated with HBV‐rebound in people with HIV (PWH) with chronic HBV (CHBV) under HBV‐active antiretroviral therapy (ART): emtricitabine (FTC)+tenofovir alafenamide (TAF) or 3TC/FTC+ tenofovir disoproxil fumarate (TDF) regimen. The present study included PWH/CHBV followed as outpatients from October 2008 to August 2023 at San Raffaele Hospital, Milan, Italy. The baseline evaluation was the date of first negative HBV‐DNA (< 10 IU/mL) after the first positive result before HBV active ART. Last evaluation (LE) was the first HBV‐rebound (≥ 10 IU/mL) or last HBV undetectable in persistently HBV‐DNA negative PWH. Odds ratio (and corresponding 95% confidence interval) of HBV‐rebound, adjusted for nadir CD4 cells, ALT levels, and ART active on both viruses was estimated by multivariable logistic regression. Of 153 PWH/CHBV under ART active on both viruses, 25 (16.3%) had at least one HBV‐rebound. Multivariate analysis at LE, showed that PWH on 3TC/FTC had a higher probability of HBV‐rebound [adjusted odds ratio, aOR=4.88 (95%confidence interval, CI = 1.28, 20.10), p = 0.02], while PWH on FTC + TAF had lower probability of HBV‐rebound [aOR = 0.05 (95%CI = 0.002, 0.27), p = 0.005], both compared to those on 3TC/FCT + TDF. Hepatitis B‐rebound was associated with higher ALT levels [aOR=1.03 (95% CI = 1.01, 1.05) per 1‐U/L higher, p = 0.001]. FTC + TAF based ART seemed to be related to a better control of HBV‐DNA than 3TC/FTC + TDF and 3TC/FTC alone. Hepatitis B‐rebound may exert an effect on liver inflammation, as suggested by the increase of transaminases levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
- Department of Infectious Diseases, Vita-Salute University San Raffaele, Milan, Italy.
Förderung
- This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Zitieren
APA
Bertoni, C., Diotallevi, S., Lolatto, R., Piromalli, G., Hasson, H., Siribelli, A., Bagaglio, S., Foppa, C. U., Castagna, A., & Morsica, G. (2025). Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy. Journal of Medical Virology. https://doi.org/10.1002/jmv.70573
Vancouver
Bertoni C, Diotallevi S, Lolatto R, Piromalli G, Hasson H, Siribelli A, et al. Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy. Journal of Medical Virology. 2025. doi:10.1002/jmv.70573
BibTeX
@article{Bertoni2025,
author = {Bertoni, Costanza and Diotallevi, Sara and Lolatto, Riccardo and Piromalli, Girolamo and Hasson, Hamid and Siribelli, Alessia and Bagaglio, Sabrina and Foppa, Caterina Uberti and Castagna, Antonella and Morsica, Giulia},
title = {Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70573}
}
EUVIMED